AI Science Tracker
EN

Ovarian recurrence risk assessment using machine learning, clinical information, and serum protein levels to predict survival in high grade ovarian cancer

Affiliation not stated in the reviewed material · 25 Jul 2023 · medicine

Discovery

Ovarian recurrence risk assessment using machine learning, clinical information, and serum protein levels to predict survival in high grade ovarian cancer

Source check: Source checked. Not independent scientific confirmation.

Finding: The July 25, 2023 Research Square v1 reports ORACLE, an elastic-net score combining clinical factors with serum proteins to stratify time-to-recurrence risk after complete response to chemotherapy for high-grade ovarian cancer. In a discovery cohort of 71 patients, the score separated recurrence outcomes; a prospectively collected independent cohort of 33 patients showed validation TTR HR 4.71 (95% CI 1.75–12.7, p=0.002). The peer-reviewed journal version appeared November 27, 2023 and reports the same study. Validation was single-institution and does not establish clinical utility.

Technology: ORACLE elastic-net risk score

Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.

AI contribution
Elastic net combines age, treatment/surgical factors, stage, CA125 and four serum proteins into the ORACLE score; the score is tuned against survival/TTR.
Test and result
ORACLE combined age, treatment/surgical factors, stage, CA125 and serum proteins. The discovery cohort included 71 patients; an independently prospectively collected 33-patient cohort had TTR HR 4.71 (95% CI 1.75–12.7, p=0.002) for the reported risk groups.
Limitation / still unknown
The validation cohort was prospectively collected at the same institution; wider external validity and clinical utility remain unestablished.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://assets-eu.researchsquare.com/files/rs-3112324/v1/67b40c92-f203-4ef6-b534-f8184d9ab326.pdf · https://www.nature.com/articles/s41598-023-47983-z

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.